2023 updated MASCC/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential

[1]  M. Shimizu,et al.  Comparison of Chemotherapy-induced Nausea and Vomiting Between Gemcitabine Plus Nab-paclitaxel Combination Chemotherapy and Gemcitabine Monotherapy in Patients With Advanced Pancreatic Cancer , 2021, AntiCancer Research.

[2]  T. Smit,et al.  The incidence of nausea in the absence of vomiting in patients receiving intravenous chemotherapy. , 2021, Annals of palliative medicine.

[3]  M. Rajabi,et al.  Evaluation of Adherence to Antiemetic Treatment Guidelines in Patients With Chemotherapy-Induced Nausea and Vomiting in Teaching Hospitals in Tehran , 2020, Journal of Cancer Education.

[4]  K. Fushimi,et al.  Analysis of concordance with antiemetic guidelines in pediatric, adolescent, and young adult patients with cancer using a large‐scale administrative database , 2019, Cancer medicine.

[5]  M. Araz,et al.  The compliance with antiemetic guidelines of Turkish medical oncologists. A survey study of Turkish Oncology Group. , 2019, Current problems in cancer.

[6]  M. Aapro,et al.  One‐Day Versus Three‐Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy‐Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data‐Based Meta‐Analysis , 2019, The oncologist.

[7]  K. Jerzak,et al.  ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients , 2018, Supportive Care in Cancer.

[8]  T. Miyoshi,et al.  A prospective, observational, multicenter study on risk factors and prophylaxis for low emetic risk chemotherapy-induced nausea and vomiting , 2017, Supportive Care in Cancer.

[9]  T. Higashi,et al.  Prescription of Prophylactic Antiemetic Drugs for Patients Receiving Chemotherapy With Minimal and Low Emetic Risk , 2017, JAMA oncology.

[10]  W. Encinosa,et al.  Changes in Antiemetic Overuse in Response to Choosing Wisely Recommendations , 2017, JAMA oncology.

[11]  R. López-López,et al.  SEOM Clinical Guideline update for the prevention of chemotherapy-induced nausea and vomiting (2016) , 2016, Clinical and Translational Oncology.

[12]  F. Caracuel,et al.  Adherence to antiemetic guidelines and control of chemotherapy-induced nausea and vomiting (CINV) in a large hospital , 2015, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

[13]  H. Friedman,et al.  Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice , 2014, Supportive Care in Cancer.

[14]  A. Molassiotis,et al.  International antiemetic guidelines on chemotherapy induced nausea and vomiting (CINV): content and implementation in daily routine practice. , 2014, European journal of pharmacology.

[15]  G. Morrow,et al.  Efficacy and safety of palonosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low emetogenic chemotherapy (LEC) , 2012, Supportive Care in Cancer.

[16]  S. Grunberg.  Obstacles to the implementation of antiemetic guidelines. , 2009, Journal of the National Comprehensive Cancer Network : JNCCN.

[17]  F. Roila,et al.  Transferring scientific evidence to oncological practice: a trial on the impact of three different implementation strategies on antiemetic prescriptions , 2004, Supportive Care in Cancer.

[18]  P. Hesketh.  Defining the emetogenicity of cancer chemotherapy regimens: relevance to clinical practice. , 1999, The oncologist.

[19]  asamy,et al.  Effectiveness of Antiemetics in the Management of Chemotherapy-induced Nausea and Vomiting in Cancer Patients Following Chemotherapy Guidelines , 2019, Indian Journal of Pharmaceutical Sciences.

[20]  I. Olver,et al.  2016 Updated MASCC/ESMO Consensus Recommendations: Controlling nausea and vomiting with chemotherapy of low or minimal emetic potential , 2016, Supportive Care in Cancer.

[21]  Myke R. Green,et al.  Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity , 2013, Journal of Cancer Research and Clinical Oncology.